New Phase III Study Of Avastin In Advanced Breast Cancer Meets Its Primary Endpoint Of Increasing The Time Patients Live

Third study confirming the benefit of Avastin in breast shows that Avastin can be effectively combined with commonly used chemotherapies Roche announced that the Avastin study RIBBON-1 met its primary endpoint of increasing the time women with breast lived without their disease advancing (known as progression-free survival) compared to chemotherapy alone, as determined by the treating physicians.


Read more

Related posts

Leave a Reply